Evidence map›Paper›PMID 31540917›Full record

ArticleDevelopment (Cambridge, England)2019

GSK-3 modulates SHH-driven proliferation in postnatal cerebellar neurogenesis and medulloblastoma.

Jennifer K Ocasio, Rolf Dale P Bates, Carolyn D Rapp, Timothy R Gershon

Open access · bronzeAbstract read
In one paragraph

Article in Development (Cambridge, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Review
  3. Effects of dopamine receptor antagonists and radiation on mouse neural stem/progenitor cells.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2024
    Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Jennifer K OcasioUNC Neuroscience Center, University of North Carolina, Chapel Hill, North Carolina 27599, USA ocasio@email.unc.edu gershont@neurology.med.unc.edu.ORCID 0000-0002-1120-2025
Rolf Dale P BatesDepartment of Neurology, UNC School of Medicine, University of North Carolina, Chapel Hill, NC 27599, USA.
Carolyn D RappDepartment of Neurology, UNC School of Medicine, University of North Carolina, Chapel Hill, NC 27599, USA.
Timothy R GershonUNC Neuroscience Center, University of North Carolina, Chapel Hill, North Carolina 27599, USA ocasio@email.unc.edu gershont@neurology.med.unc.edu.ORCID 0000-0001-7034-6400
University of North Carolina at Chapel Hill · US

Funding

Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI David Darr · 1985 to 2026
$201.5M
UNC-CH CENTER FOR ENVIRONMENTAL HEALTH &SUSCEPTIBILITYP30ES010126 · NIEHS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Stephanie Engel · 2001 to 2026
$36.3M
UNC Neuroscience Center Research Cores: MicroscopyP30NS045892 · NINDS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ZYLKA, MARK J. · 2003 to 2022
$11.5M
RESEARCH TRAINING IN THE NEUROSCIENCEST32NS007431 · NINDS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Juan Song, Mark J. Zylka · 1997 to 2026
$10.0M
Targeting the MEKK2-ERK5 Signaling Node in Triple Negative Breast CancerU54CA156733 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI EARP, H. SHELTON · 2010 to 2020
$9.7M
Preclinical CoreU54HD079124 · NICHD · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BELGER, AYSENIL · 2013 to 2019
$8.0M
Bcl-xL-regulated apoptosis in cerebellar development and medulloblastoma treatmentR01NS102627 · NINDS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI GERSHON, TIMOTHY · 2018 to 2022
$1.8M
Defining the crucial role of MAGOH in cerebellar development and the potential for targeting the EJC in medulloblastoma treatmentR01NS106227 · NINDS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI GERSHON, TIMOTHY · 2018 to 2023
$1.7M
Glycolytic regulation of cerebellar development and medulloblastoma tumorigenesisR01NS088219 · NINDS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI GERSHON, TIMOTHY · 2015 to 2019
$1.6M
Proliferation of cerebellar neural progenitors and Shh-driven medulloblastoma requires suppression of WNT by GSK-3F31NS100489 · NINDS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI OCASIO ADORNO, JENNIFER KARIN · 2017 to 2018
$70k
NCI NIH HHS P30 CA016086NCI NIH HHS U54 CA156733NICHD NIH HHS U54 HD079124NIEHS NIH HHS P30 ES010126NINDS NIH HHS F31 NS100489NINDS NIH HHS P30 NS045892NINDS NIH HHS R01 NS088219NINDS NIH HHS R01 NS102627NINDS NIH HHS R01 NS106227NINDS NIH HHS T32 NS007431
6 · The paper itself

Abstract

Cerebellar development requires regulated proliferation of cerebellar granule neuron progenitors (CGNPs). Inadequate CGNP proliferation causes cerebellar hypoplasia whereas excessive CGNP proliferation can cause medulloblastoma, the most common malignant pediatric brain tumor. Although sonic hedgehog (SHH) signaling is known to activate CGNP proliferation, the mechanisms downregulating proliferation are less defined. We investigated CGNP regulation by GSK-3, which downregulates proliferation in the forebrain, gut and breast by suppressing mitogenic WNT signaling in mouse. In striking contrast to these systems, we found that co-deleting

Indexed as

AminopyridinesAnimalsCell ProliferationCyclin-Dependent Kinase Inhibitor p21Glycogen Synthase Kinase 3Hedgehog ProteinsMedulloblastomaMiceMice, Mutant StrainsNeural Stem CellsNeurogenesisPyrimidinesSignal TransductionAminopyridinesCdkn1a protein, mouseChir 98014Cyclin-Dependent Kinase Inhibitor p21Glycogen Synthase Kinase 3Hedgehog ProteinsPyrimidinesCell cycleCerebellar developmentGSK-3MedulloblastomaMousePostnatal neurogenesisWNT

Identifiers

PMID31540917
PMCPMC6826032
OpenAlexW2974469003

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.